Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
ID: 357190Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357190

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-25-173.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE), aimed at supporting innovative preclinical research projects that investigate the effects of radionuclide-based therapeutics on normal tissues, tumor cells, and the tumor microenvironment. This initiative encourages proposals that explore new targets for radiopharmaceuticals, develop drug combination strategies, and enhance theranostic capabilities, with a budget cap of $275,000 over a two-year period. The STRIPE program is critical for advancing cancer treatment methodologies by facilitating the transition of promising preclinical findings into clinical applications. Interested applicants can submit proposals starting January 16, 2025, and should direct inquiries to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PA-25-173-Full-Announcement.html
    PA-25-173.html
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE), managed by the National Cancer Institute (NCI). This initiative aims to support R21 research projects that investigate the effects of various types of radiation used in radionuclide-based therapeutics on normal tissues, tumor cells, and the tumor microenvironment. Applicants can submit proposals starting January 16, 2025, with a budget cap of $275,000 over two years, focusing on novel preclinical research rather than clinical trials. Key research priorities include exploring new targets for radiopharmaceuticals, developing drug combination strategies, and enhancing theranostic capabilities. Collaborative proposals are encouraged, particularly those involving multiple principal investigators with expertise in cancer biology and radiotherapy. Importantly, the STRIPE program seeks to advance preclinical studies, facilitating the transition of promising findings into clinical applications. The program emphasizes adherence to detailed application instructions and regulatory compliance to enhance research quality and effectiveness. This grant represents a significant opportunity for advancing cancer treatment methodologies through innovative research.
    Similar Opportunities
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE)" aimed at advancing cancer therapeutics through research projects that utilize radionuclide-based therapies. This initiative specifically seeks R01 research proposals that investigate the effects of various radiation types on normal tissues, tumor cells, and the tumor microenvironment, with a focus on novel targeting strategies and pharmacodynamic biomarkers. The STRIPE program is critical for enhancing the understanding of radiopharmaceuticals in cancer treatment, with applications limited to direct costs of $500,000 per year and a maximum project duration of five years. Interested applicants must adhere to NIH guidelines, with submission deadlines starting January 5, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments" (STRIPE) through the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support preclinical research focused on the effects of radionuclide-based therapeutics on normal tissues, tumor cells, and their microenvironments, encouraging collaborative applications that explore innovative therapeutic strategies. The maximum budget for successful proposals is set at $275,000 in direct costs over a two-year period, with applications due by various dates until October 16, 2025. Interested applicants can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE)" aimed at advancing research in cancer therapeutics. This initiative invites R01 research project applications that utilize innovative cancer biology methods to investigate the effects of radionuclide-based therapies on normal tissues, tumor cells, and the tumor microenvironment. The STRIPE program is critical for fostering research that may lead to effective treatments for metastatic diseases, emphasizing collaboration among experts in the field while excluding applications focused solely on clinical trials or computational methods. Interested applicants can apply for grants with a budget ceiling of $500,000 per year for a maximum project period of five years, with the application deadline set for May 7, 2025. For further inquiries, applicants may contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-139.html.
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations" (PAIRS) to support R21 research projects focused on identifying actionable vulnerabilities in tumors that respond to radiation therapy. The objective is to develop innovative radiation-synthetic combination strategies that enhance anticancer treatments, with applications ranging from pre-clinical research to early clinical trials. This initiative underscores the significance of precision medicine in oncology and encourages collaborative efforts to address complex cancer challenges. Eligible applicants include various institutions and organizations, with a funding ceiling of $275,000 over two years, and applications are due by September 7, 2025. For more information, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the official announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-199.html.
    Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)" aimed at advancing research in cancer treatment through innovative synthetic vulnerabilities linked to radiation therapy. This initiative seeks R01 research projects that explore actionable vulnerabilities in tumors that can be paired with radiation responses, with the goal of developing effective anticancer strategies and integrating them into precision medicine. Eligible applicants include a wide range of entities such as higher education institutions, nonprofits, and governmental organizations, with applications due by 5 PM local time on September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAR-22-198.html.
    Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems)" aimed at supporting research into acute and delayed radiation injuries. This initiative seeks to develop innovative extracorporeal systems that accurately replicate human responses to radiation, facilitating the exploration of injury mechanisms and the testing of medical countermeasures. The funding, structured as a U01 cooperative agreement, has a total budget of $4 million, with plans to award six to eight grants in FY 2026. Interested applicants should note that the submission deadline is February 7, 2025, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at supporting advanced pre-clinical research in nanotechnology-based cancer diagnostics and therapeutics. This initiative encourages innovative projects that utilize nanoparticle formulations or nano-devices to address significant clinical objectives in cancer treatment, with a focus on enhancing treatment efficacy through combination therapies and immunotherapy. Funding is available up to $475,000 annually for a maximum of four years, with applications accepted from eligible institutions including higher education entities, nonprofits, and government organizations. Interested applicants should refer to the detailed application process outlined on Grants.gov and the NIH ASSIST system, with key deadlines spanning from April 2025 to November 2027. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" aimed at advancing research in cancer biology and oncology through the application of nanotechnology. This initiative encourages proposals that address significant challenges in these fields by focusing on mechanistic studies of nanomaterial interactions with biological systems, rather than clinical applications. The program is particularly important for enhancing the understanding of nanoparticle delivery mechanisms and improving diagnostic technologies in cancer treatment. Interested applicants can apply for grants with a budget cap of $475,000 per year over a maximum project period of five years, with applications due by May 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html.
    Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a funding opportunity titled "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies." This initiative aims to support innovative research projects that investigate the adverse effects of cancer therapies, particularly those that lead to chronic comorbidities or delayed sequelae, with a focus on understanding the underlying mechanisms and developing therapeutic strategies to mitigate these long-term issues. The funding is open to a diverse range of applicants, including educational institutions, non-profits, and foreign organizations, and requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications must be submitted electronically by January 5, 2025, with awards contingent on available funding and merit assessed through NIH's peer-review process. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.